GEHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
GE Healthcare Technologies Inc (GEHC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has a strong growth outlook, positive technical indicators, and recent FDA approval for innovative technology, which supports long-term potential. Despite a slight decline in net income and EPS in the latest quarter, revenue growth and bullish analyst ratings indicate a favorable investment opportunity.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram of 0.491, and an RSI of 69.565, which is neutral but leaning towards overbought territory. The stock is trading above its 20-day and 100-day SMAs, indicating a positive trend. Key support and resistance levels are Pivot: 82.148, R1: 86.144, S1: 78.153, R2: 88.613, and S2: 75.684.
FDA approval for next-generation SIGNA MRI technology, which enhances sustainability and reduces helium dependency.
Bullish analyst sentiment with multiple price target increases and positive outlooks for
Revenue growth of 7.13% YoY in Q4
SwingMax signal issued on 2026-02-17, indicating a buy-low opportunity.
Hedge funds are selling, with a 129.92% increase in selling activity over the last quarter.
Net income and EPS declined by -18.31% and -17.83% YoY, respectively, in Q4
Post-market price decline of -1.08%, indicating short-term bearish sentiment.
In Q4 2025, revenue increased by 7.13% YoY to $5.698 billion, demonstrating strong top-line growth. However, net income dropped by -18.31% YoY to $589 million, and EPS declined by -17.83% YoY to 1.29. Gross margin also decreased by -7.22% YoY to 39.68%. Despite these declines, the company maintains a solid revenue growth trajectory.
Analysts have raised price targets recently, with Barclays increasing to $87, Stifel to $98, Morgan Stanley to $85, Piper Sandler to $94, and Jefferies to $105. The consensus reflects optimism about GEHC's growth potential, supported by solid Q4 results and a positive 2026 outlook.
